Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 29, 2015 10:44 AM ET


Company Overview of Cardiome Pharma Corp.

Company Overview

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It has operations in Canada, the United States, and Europe. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.


6th Floor

Vancouver, BC V6J 4S7


Founded in 1986





Key Executives for Cardiome Pharma Corp.

Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $650.0K
Chief Financial Officer
Total Annual Compensation: $275.0K
Chief Operating Officer
Total Annual Compensation: $240.0K
Corporate General Counsel
Age: 55
Total Annual Compensation: $248.5K
Compensation as of Fiscal Year 2014.

Cardiome Pharma Corp. Key Developments

Cardiome Pharma Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cardiome Pharma Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss of $3.9 million or $0.23 per share compared to a net loss of $3.1 million or $0.20 per share for the three months ended March 31, 2014. Revenue was $5.5 million, compared to $7.6 million a year ago. The decrease was due primarily to foreign exchange, timing of distributor sales, and a decrease in AGGRASTAT® sales due to generic competition. Operating loss was $2.657 million against $2.681 million a year ago. Loss before income taxes was $3.780 million against $3.017 million a year ago. Net cash used in operating activities was $3.168 million against $9.294 million a year ago. Purchase of property and equipment were $0.89 million against $0.3 million a year ago. Increase in intangible assets was $0.13 million against $0.12 million a year ago.

Cardiome and AOP Orphan Pharma Enter ESMOCARD Commercialization Agreement

Cardiome Pharma Corp. announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP's cardiovascular products, ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride) in Italy, France, Spain and Belgium. Financial details of the agreement were not disclosed.

Cardiome Pharma Corp. to Report Q1, 2015 Results on May 13, 2015

Cardiome Pharma Corp. announced that they will report Q1, 2015 results at 8:00 AM, US Eastern Standard Time on May 13, 2015

Similar Private Companies By Industry

Company Name Region
iJuana Cannabis inc. Americas
Klox Technologies Inc. Americas
Cadherin Biomedical Inc. Americas
Provalt Life Sciences Corporation Americas
Immunitor Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cardiome Pharma Corp., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at